跳至主要内容
临床试验/NCT05757817
NCT05757817招募中不适用

Evaluation of the Benefit of a New Surgical Procedure According to IDEAL Recommendations for ORL Cancer Patients: the External Pudendal Flap Used as a New Free Flap for Oral Cavity/Oropharyngeal Reconstruction to Limit Donor Site Sequelae

Institut Claudius Regaud6 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2023年11月8日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
40
试验地点
6
主要终点
The occurrence of a limiting complication. Limiting complications are defined as total flap necrosis (flap failure) or donor site infection (Fournier Gangrene) within 4 weeks of the experimental procedure.

研究概览

简要总结

This is a phase 1b, multicenter, non-randomized prospective study involving an innovation phase (IDEAL-1) followed by a prospective development phase (IDEAL-2A) designed to evaluate the safety and feasibility of oral/oropharyngeal reconstruction with the external pudendal free flap in two groups of patients.

A maximum of 40 patients (20 patients per group) will be included in this IDEAL-1/2A phase study.

Stage IDEAL-1: Innovation phase. The main objective is to evaluate the feasibility in terms of limiting surgical complications of a STEPA flap reconstruction in two groups of patients (Cohort: Male, Female).

Stage IDEAL-2A: Prospective development phase. The main objective is to describe the complication profile of the surgical procedure in these two patient populations.

Each patient will be followed during 12 months after the end of complete treatment (surgery ± adjuvant treatment).

A complementary study (observational study) of 250 patients will also be conducted to evaluate the acceptability of the technique (reconstruction by external pudendal flap) by the patients and to describe the factors associated with this acceptability.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient with a histologically proven diagnosis of head and neck squamous cell carcinoma (HNSCC) of the oral cavity or oropharynx.
  • Patient whose disease is classified UICC TNM stade (8th edition) : T0-4a N0/N2c M0 (no distant metastasis M0).
  • Patient whose oral cavity or oropharynx reconstruction requires a free fasciocutaneous flap according to an experienced oncology surgeon.
  • Patient OMS 0-
  • Patient with no contraindication to surgery.
  • Patient affiliated to a Social Health Insurance in France.
  • Patient able to participate and willing to give informed consent prior performance of any study-related procedures and to comply with the study protocol.

排除标准

  • Patient with history of prior cervical surgery and/or radiation to the head and neck.
  • History of pelvic surgery and/or radiation to the pelvic area.
  • Patients with a contraindication to any form of sedation.
  • Patient with irreversible coagulopathy.
  • Patient with a contraindication to a CT scan or an injection of iodinated contrast medium.
  • Patient with active autoimmune disorders requiring immunosuppressive therapy, defined as receiving steroids (dose > 10 mg of prednisone or equivalent) or other immunosuppressive therapy.
  • Pregnant or breastfeeding women.
  • Patient with another co-existing malignancy at the time of inclusion or any other significant medical, psychiatric, or surgical condition currently not controlled by treatment, which may interfere with the conduct of the study.
  • Patient with diabetes (type 1 or 2).
  • Patient with a BMI > 30kg/m².
  • Any psychological, family, geographic or sociological condition that does not allow for compliance with the medical follow-up and/or procedures provided for in the study protocol .
  • Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).

结局指标

主要结局

The occurrence of a limiting complication. Limiting complications are defined as total flap necrosis (flap failure) or donor site infection (Fournier Gangrene) within 4 weeks of the experimental procedure.

时间窗: 4 weeks for each patient

次要结局

  • 4. The aesthetic evaluation will be performed according to a Likert scale (Likert scale: not at all satisfied, somewhat not satisfied, neither dissatisfied nor satisfied, somewhat satisfied, very satisfied).(12 months for each patient)
  • The postoperative complications will be evaluated according to the NCI-CTCAE version n°5(12 months for each patient)
  • The pain will be assessed according to a Likert scale between 0 (no pain) and 10 (worst pain).(12 months for each patient)
  • The functional capacity of swallowing will be assessed via the Performance Status Scale for Head and Neck cancer patients - PSS-HN (Scales are: Normalcy of Diet, Public Eating, and Understandability of Speech).(12 months for each patient)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (6)

Loading locations...

相似试验

进行中(未招募)
不适用
Clinical Study Evaluating the Efficacy and Safety of CID v2.2 in Glaucoma SurgeryGlaucoma, Open-AngleGlaucoma, Narrow Angle
NCT05625958Ciliatech29
已完成
不适用
An Investigator-initiated, Explorative Trial Evaluating the Effect of SAT-008 in Healthy AdultsAllergy and Immunology
NCT04916145Seoul National University Bundang Hospital42
已完成
2 期
Safety, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer's DiseaseAlzheimer Disease
NCT03402503IntelGenx Corp.52
终止
1 期
A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).Advanced Hepatocellular Carcinoma
NCT05975645Chia Tai Tianqing Pharmaceutical Group Co., Ltd.29
进行中(未招募)
1 期
A multi-stage clinical study to develop a non-invasive Short Synacthen Test (SST) with nasally administered synacthen and salivary cortisol. The validated non-invasive SST will be used to establish normative data in children and to detect adrenal suppression in asthmatic children. - The development of a non-invasive Short Synacthen Test - NeSST StudyIn stages 1+2 of the study healthy volunteers will be used to determine the bioequivalence of nasal synacthen with 1 microgram of intravenous synacthen. Stage 3 will use healthy children to establish normal ranges for the adrenal response to a low-dose synacthen test. In stage 4 adrenal function in asthmatic individuals on inhaled corticosteroids will be studied.MedDRA version: 9.0Level: PTClassification code 10001367Term: Adrenal InsufficiencyMedDRA version: 9.0Level: PTClassification code 10006482Term: Bronchospasm
EUCTR2009-013355-29-GBSheffield Children's NHS Foundation Hospital258